November 23, 2021 5:10pm

In my 35 covered cell and gene therapy sector equities, a train of thirteen (13) downdraft sessions was broken

Pre-open indication results: 7 HITs, 2 MISS

The Biostage (BSTG) Chronicles: Tuesday closed $0.00 with 0 shares traded after Monday closed down -$0.30 to $2.30 with 1,141 shares traded. When are they going to admit they are a failing entity and do something about the current management? Faking it until they can’t make it!

Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public markets investor to a journalist and pundit; it is that your life and your bank account are largely tied to your questioning of price targets.

The Dow closed UP +194.55 points (+0.55%); the S&P closed UP +7.76 points (+0.17%) while the Nasdaq closed DOWN -79.62 points (-0.50%)

 

Henry’omics:

The Nasdaq fell sharply for the second-straight day on Tuesday as continued risk dis-interest appeared to put pressure on stem, cell and gene therapy sector equities as volume was low yet, the VIX closed up +0.21 or +1.10% to 19.38. Following along to the downside were the IBB at -0.44% and the XBI closed up +0.08%.

Pains and gains:

  • Homology Medicine (FIXX) reached a 52-week low of $5.01 and surged to $5.20
  • Ultragenyx Pharmaceuticals (RARE) reached a 52-week low of $74.91 and surged to $77.20
  • Cellectis SA (CLLS) reached a 52-week low of $8.25 and surged to $8.34
  • Precigen (PGEN) reached a 52-week low of $3.47 and surged to $3.63  
  • CRISPR Therapeutics (CRSP) reached a 52-week low of $79.19 surged to $80.08
  • Fate Therapeutics (FATE) reached a 52-week low of $51.62 surged to $52.19
  • bluebird bio (BLUE) reached a 52-week low of $10.23 and surged to $10.73
  • XBI also reached a 52-week low of 117.00

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Tuesday opened negative at 4 ups/28 downs, 2 flats and 1 acquired, stayed negative at the mid-day at 9/24, 1 flat and 1 acquired, ending with a barely positive close of 17 ups/16 downs, 1 flat and 1 acquired;
  • Monday opened negative at 6 ups/27 downs, 1 flat and 1 acquired, stayed negative at the mid-day at 7/26, 1 flat and 1 acquired, ending with a negative close of 6/28 and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “weighing the risks of low volume and a shortened week while catalysts aren’t apparent.” … https://www.regmedinvestors.com/articles/12195

 

Pre-open indication results: 7 HITs: < Biostage (BSTG -$0.00), Applied Genetic Technologies (AGTC - $0.08), Athersys (ATHX -$0.08), CRISPR Therapeutics (CRSP -$0.51), Intellia Therapeutics (NTLA -$8.69), Regenxbio (RGNX +$0.15), Vericel (VCEL +$0.04), > and 2 MISS < Fate Therapeutics (FATE -$0.26), Verastem (VSTM -$0.02)>

 

The Biostage (BSTG) Chronicles: Tuesday closed $0.00 with 0 shares traded following Monday closed down again -$0.30 with 1,141 shares traded, Friday’s -$0.39 to $2.60 with 8,625 shares traded after Thursday closed with 17 shares traded, Wednesday’s $0.00 with 2,889 shares traded and last Tuesday’s +$0.39 with 2,687 shares traded. Where is the SEC and Nasdaq monitoring?

  • WHY pump the share price with NO clinical trial from a one (1) and 3/4-year-old IND and a negligence rejection of reimbursement in a terminal death suit.
  • What’s there to invest in, the “Sword of Damocles” hanging over the companies non-going operations?

 

Key Metric - volume

Sector volume HIGHER with 7 of the 17-upside having higher than the 3-month average volume with INCREASING volume of 10 of 16-downside having higher than the 3-month average volume;

Outstanding Upside Volume:

  • Solid Biosciences (SLDB) closed up +$0.09 with 3.188 m shares traded
  • Precigen (PGEN +$0.05 with 2.435 m shares traded

 

There are clear winners and losers

Jumping with share pricing momentum (10 of 17):

  • Chinook Therapeutics (KDNY +$1.13),
  • AxoGen (AXGN +$0.29 after Monday’s +$0.35),
  • Mesoblast (MESO +$0.22 after Monday’s +$0.01),
  • bluebird bio (BLUE +$0.19),
  • Brainstorm Cell Therapeutics (BCLI +$0.16),
  • Regenxbio (RGNX +$0.15 after Monday’s +$0.21),
  • Editas Medicine (EDIT +$0.15 after Monday’s -$1.49),
  • Voyager Therapeutics (VYGR +$0.14),
  • Alnylam Pharmaceuticals (ALNY +$0.1 after Monday’s +$6.01),
  • Solid Biosciences (SLDB +$0.09),

Hammered in today’s market (10 of 16):

  • Intellia Therapeutics (NTLA -$8.69 after Monday’s -$4.78),
  • ReNeuron (RENE.L -$4.50 after Monday’s+$1.00),
  • uniQure NV (QURE -$0.70 after Monday’s -$0.82),
  • Ultragenyx (RARE-$0.62),
  • CRISPR Therapeutics (CRSP -$0.51),
  • Global Blood Therapeutics (GBT -$0.32 after Monday’s -$1.06),
  • Ionis Pharmaceuticals (IONS -$0.32 after Monday’s -$1.34),
  • Fate Therapeutics (FATE -$0.26 after Monday’s -$3.52),
  • Sage Therapeutics (SAGE -$0.17 after Monday’s -$0.99),
  • Athersys (ATHX -$0.08 after Monday’s +$0.095),

Closing Flat:

  • 1 – Biostage (BSTG) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed down -0.44% and XBI closed up +0.08%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +0.21 points or +1.10% at 19.38

 

November, the second month of Q4/21:

Tuesday closed positive with 17 incliners, 16 decliners, 1 flat and 1 acquired

Monday (11/22) closed negative with 6 incliners, 28 decliners and 1 acquired

 

The BOTTOM LINE:  a ray of sunshine on the sector or maybe a bottom was finally found.

  • Q3 earnings reporting season began the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.

Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.